70.03 USD
↗ 1.83 (2.68%)AT CLOSE (03:59 PM EDT)
Tarsus Pharmaceuticals, Inc. Common Stock
TARSNASDAQ • USD
70.02
↘ 0.02 (0.02%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
70.02
↘ 0.02 (0.02%)
Market: CLOSED
Tarsus Pharmaceuticals, Inc. Common Stock (TARS) trades at $70.01 per share. The technical outlook is "Sell" and the fundamental picture shows "Neutral". Notable factors include a robust Altman Z-Score, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Oct 26, 2026.
Open?$68.37
High?$71.62
Low?$68.36
Prev. Close?$68.20
Volume?1.2M
Avg. Volume?908.1K
VWAP?$70.04
Rel. Volume?1.32x
Bid / Ask
Bid?$58.27 × 100
Ask?$84.99 × 100
Spread?$26.72
Midpoint?$71.63
Valuation & Ratios
Market Cap?3.2B
Shares Out?49.3M
Float?37.5M
Float %?85.6%
P/E Ratio?N/A
P/B Ratio?9.20
EPS?-$1.00
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Employees
370
Market Cap
3.2B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2020-10-16
Address
15440 LAGUNA CANYON ROAD
IRVINE, CA 92618
Phone: (949) 409-9820
IRVINE, CA 92618
Phone: (949) 409-9820
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?23
Z-Score?100
Momentum?94
Short Sent.?36
Piotroski F-Score?3/9Weak
Altman Z-Score?7.69Safe
Confidence?57%Low
Short InterestHigh
Short % of Float?15.26%High
Short Interest?5.7M
Days to Cover?5.7
Free Float37.5M
Avg Daily Volume1.0M
Settlement Date2026-10-15
Financial Health
Current Ratio?3.20Strong
Quick Ratio?3.17Strong
Cash Ratio?1.16Strong
Debt/Equity?0.21Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score60/100
P/E?N/A▾
P/B?9.20HIGH▾
Peers100
S&P20
P/S?5.26FAIR▾
Peers100
S&P27
P/FCF?57.0PRICEY▾
Peers100
S&P8
EV/EBITDA?-59.2CHEAP▾
S&P97
EV/Sales?5.05FAIR▾
Peers100
S&P36
Returns & Efficiency
ROE?-13.5%WEAK▾
S&P9
ROA?-7.7%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$56.0M
Enterprise Value?$3.1B
Fundamentals ratios updated end of day